Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys

Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia

(2022) Bo Hu et al.   Science Advances

An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif

(2022) Deepa Balasubramaniam et al.   JOURNAL OF LIPID RESEARCH

Novel lipid-lowering therapies targeting ANGPTL3 and Lp(a)

(2022) Gregory B. Lim   Nature Reviews Cardiology

Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia

(2021) Farzahna Mohamed et al.   CURRENT OPINION IN LIPIDOLOGY

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

(2021) Sander F. Garrelfs et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nonclinical Disposition and PK/PD Properties of GalNAc-conjugated siRNA Are Highly Predictable and Build Confidence in Translation to Man

(2021) Robin McDougall et al.   DRUG METABOLISM AND DISPOSITION

Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

(2021) Zahid Ahmad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Triglycerides and Residual Atherosclerotic Risk

(2021) Sergio Raposeiras-Roubin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation

(2021) Hao Cui et al.   ACS Omega

GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics

(2021) Lokesh Thangamani et al.   PHARMACOLOGICAL RESEARCH

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels

(2021) Ren Zhang   Frontiers in Cardiovascular Medicine

Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3

(2021) Gerald F Watts et al.   Future Cardiology

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions

(2020) Aliza Hussain et al.   Current Atherosclerosis Reports

Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective

(2020) Xiaoming Jia et al.   CARDIOVASCULAR DRUGS AND THERAPY

LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase

(2020) Liya Wu et al.   CIRCULATION RESEARCH

Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations

(2020) Yi Wang   CURRENT GENE THERAPY

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

(2019) Nicholas A. Marston et al.   CIRCULATION

Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study

(2019) Massimiliano Ruscica et al.   European Journal of Preventive Cardiology

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

(2018) Aaron D. Springer et al.   Nucleic Acid Therapeutics

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

(2017) Sushrut Kamerkar et al.   NATURE

Angiopoietin-like 3 in lipoprotein metabolism

(2017) Sander Kersten   Nature Reviews Endocrinology

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of siRNAs

(2017) Xinyun Song et al.   Molecular Therapy-Nucleic Acids

siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes

(2015) Shigeo Matsuda et al.   ACS Chemical Biology

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

(2015) Viktoria Gusarova et al.   JOURNAL OF LIPID RESEARCH

Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins

(2015) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

Carotid Artery Plaque and LDL-to-HDL Cholesterol Ratio Predict Atherosclerotic Status in Coronary Arteries in Asymptomatic Patients with Type 2 Diabetes Mellitus

(2013) Kazuya Fujihara et al.   Journal of Atherosclerosis and Thrombosis

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

(2013) Ilenia Minicocci et al.   JOURNAL OF LIPID RESEARCH

Rhesus Macaques Develop Metabolic Syndrome With Reversible Vascular Dysfunction Responsive to Pioglitazone

(2011) Xiuqin Zhang et al.   CIRCULATION

Rational design of cationic lipids for siRNA delivery

(2010) Sean C Semple et al.   NATURE BIOTECHNOLOGY

Biomarkers of premature atherosclerosis

(2009) Anna-Maria Kampoli et al.   TRENDS IN MOLECULAR MEDICINE

Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry

(2008) Yan Zou et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY